Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
If the remaining trials produce positive results, Eli Lilly is expected to submit a New Drug Application (NDA) to the FDA in late year
Obicetrapib Obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, is being studied in two pivotal phase 3 trials, PREVAIL and BROADWAY
Parietal cells in the stomach produce a glycoprotein called intrinsic factor, which is necessary to absorb vitamin B12 in the terminal ileum
Led by Jamie Gabel, MS PA-C, our team combines extensive expertise in metabolic medicine with a dedication to excellence and innovation
US$ 25.74
US$ 25.25
US$ 24.24
US$ 28.30
US$ 20.67
US$ 21.55
US$ 25.23
US$ 20.96
